RxDoctor Payments Data

Scot Callahan, MD

Otolaryngology · Enterprise, ALNPI 1023096427

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.6% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AstraZeneca at 35.1% of the total.

$2,388in general payments, 2019–2025

Across 123 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$839
  • Sanofi$693
  • Regeneron Healthcare Solutions, Inc.$443
  • Optinose US, Inc.$140
  • Acclarent, Inc$89
  • Integra Lifesciences Corporation$38
  • plus $147 from 7 others

What the payments were for

  • Food & beverage$2,35499%
  • Education$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,388 in reported general payments places this provider in the 60th percentile of 155 otolaryngology providers in Alabama.

See all otolaryngology providers in Alabama

Medicare billing

Part B allowed, 2024
$170,572
Medicare patients
290
Services billed
2,749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab25$92,626
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$14,716
Breo ElliptaFluticasone/Vilanterol17$6,365
Arnuity ElliptaFluticasone Furoate16$6,162
Mometasone Furoate61$5,060
DuleraMometasone/Formoterol14$4,627
Ipratropium Bromide116$3,961
Cromolyn Sodium12$2,532
Azelastine Hcl56$2,381
Azithromycin116$2,291
Esomeprazole Magnesium24$2,091
Fluocinolone Acetonide Oil42$2,055
Levocetirizine Dihydrochloride155$1,954
Montelukast Sodium142$1,942
Fluticasone Propionate117$1,544

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckDulera$16$4,62714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 155 otolaryngology providers in Alabama.

Other otolaryngology in Enterprise

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →